Impact of Asthma Controller Medications on Clinical, Economic, and Patient-Reported Outcomes

Article ID	Journal	Published Year	Pages	File Type
2999456	Mayo Clinic Proceedings	2009	10 Pages	PDF

Abstract

Inhaled corticosteroids were associated with a lower risk of INP/ED visits, and a lower cost if adherence was achieved. When adherence cannot be achieved, LMs may be a reasonable alternative. Combination therapy with ICS plus a long-acting Î²-agonist was associated with better or equivalent clinical, economic, and patient-reported outcomes.

Keywords

Mini-Asthma Quality of Life Questionnaire ATAQ INP SABA WPAI NAEPP Mini-AQLQ HIPAA ICS MPR ICD-9-CM OCs Long-acting β-agonist leukotriene modifier Short-acting β-agonist emergency department National Asthma Education and Prevention Program Inpatient Chronic obstructive pulmonary disease COPD LABA body mass index BMI international classification of diseases, ninth revision, clinical modification Health Insurance Portability and Accountability Act Medication possession ratio Asthma Therapy Assessment Questionnaire Work Productivity and Activity Impairment oral corticosteroid Inhaled corticosteroid